World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 October 2017
Main ID:  NCT01078454
Date of registration: 27/02/2010
Prospective Registration: Yes
Primary sponsor: National Cancer Institute (NCI)
Public title: Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Scientific title: A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation
Date of first enrolment: November 2010
Target sample size: 11
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01078454
Study type:  Interventional
Study design:   
Phase:  Phase 3
Countries of recruitment
United States
Contacts
Name:     Angela Dispenzieri, M.D.
Address: 
Telephone:
Email:
Affiliation:  Mayo Clinic
Key inclusion & exclusion criteria

Inclusion Criteria:

- Histologically confirmed diagnosis of systemic light-chain amyloidosis

- Histologic diagnosis of disease must be confirmed by pathology (positive Congo
red stain with green birefringence on polarized light microscopy)

- Genetic testing must be negative for transthyretin mutations associated with
hereditary amyloidosis (required in patients who are African-American or who
present with peripheral neuropathy as the dominant organ involvement)

- Measurable disease, defined by >= 1 of the following:

- Serum M-protein >= 1 g/dL by serum protein electrophoresis (SPEP)

- Difference between involved and uninvolved free light chain be >4.0mg/dL provided
the kappa to lambda free light chain (FLC) ratio is abnormal

- Symptomatic organ involvement* (heart, kidney, liver/gastrointestinal tract,
peripheral nervous system, or soft tissue), defined as any of the following:

- NOTE: *Carpal tunnel syndrome skin purpura or the presence of vascular amyloid on
a bone marrow biopsy alone are not sufficient to meet criteria for "symptomatic
organ involvement"

- Renal involvement is defined as proteinuria (predominantly albumin) > 0.5 g/day
by 24-hour urine collection

- Cardiac involvement is defined as the presence of a mean left ventricular wall
thickness of > 12 mm by echocardiogram in the absence of a history of
hypertension or valvular heart disease or in the presence of unexplained low
voltage (< 0.5 mV) by electrocardiogram

- Hepatic involvement is defined as hepatomegaly or an alkaline phosphatase > 1.5
times upper limit of normal (ULN)

- Peripheral nerve involvement is defined by clinical history or abnormal sensory
and/or motor findings on neurologic exam

- Gastrointestinal (GI) involvement is defined as gross GI bleeding or diarrhea (at
least 4 stools per day over baseline); a positive GI biopsy is not sufficient to
document clinical involvement

- Autonomic nerve involvement is defined as orthostasis, symptoms of nausea or
dysgeusia, gastric atony by gastric emptying scan, diarrhea, or constipation

- Soft tissue and lymphatic involvement may be ascertained based on classic
physical exam findings (macroglossia, shoulder pad sign, raccoon eyes, carpal
tunnel syndrome, synovial enlargement, firm enlarged lymph nodes) or biopsy

- Ineligible for autologous stem cell transplantation with melphalan 200 mg/m^2 or
refuses to undergo transplantation

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Amyloid cardiac biomarker stage I or II disease

- The amyloid cardiac staging system is based on NT-proBNP and troponin-T levels.
If troponin T (cTnT) is not available at local institution then troponin I (cTnI)
may be used. Thresholds for cTnT, cTnI, and NT-proBNP are < 0.035 ug/L, < 0.1
ug/L, and < 332 ng/L, respectively. Stage I patients have both troponin-T (or I)
and NT-proBNP below the threshold. Stage II patients have either troponin-T (I)
or NT-proBNP above the threshold. Stage III patients have troponin-T (or I) and
simultaneous NT-proBNP above the threshold. Stage III patients are further
classified as "better risk" if NT-proBNP is over 332 ng/L but less than 6000 ng/L

- Negative pregnancy test

- Fertile patients must use effective contraception

- The absence of supine systolic blood pressure < 100 mmHg and difficult to manage
symptomatic orthostatic hypotension

- Absolute neutrophil count (ANC) > 1,500/mm^3

- Platelet count > 140,000/mm^3

- Hemoglobin > 10 g/dL

- Total bilirubin < 2.5 mg/dL

- Alkaline phosphatase < 5 times upper limit of normal (ULN)

- Aspartate aminotransferase (AST) < 3 times ULN

- Creatinine clearance > 30 mL/min

- Bone marrow plasma cells < 30%

- Human immunodeficiency virus (HIV)-positivity allowed provided the following criteria
are met:

- No history of acquired immunodeficiency syndrome (AIDS)-defining events including
history of CD4 cell count < 200/mm^3

- Current CD4 cell count >= 350/mm^3

- Not receiving zidovudine or stavudine

- No secondary amyloidosis

- More than 3 weeks since radiotherapy

- Enrollment of subjects who require radiotherapy (which must be localized in field
size) should be deferred until the radiotherapy is completed and 3 weeks have
elapsed since the last date of therapy

- More than 14 days since prior and no concurrent participation in clinical trials with
other investigational agents not included in this trial

Exclusion Criteria:

- Pregnant or nursing

- Clinically overt myeloma (hypercalcemia or lytic bone lesions)

- Prior chemotherapy or radiotherapy for the treatment of myeloma or systemic
light-chain amyloidosis

- History of sustained ventricular tachycardias

- Cardiac syncope

- Uncompensated New York Heart Association (NYHA) class III or IV congestive heart
failure

- Uncontrolled infection

- Active malignancy within the past 5 years except for adequately treated basal cell or
squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I
cancer currently in complete remission

- Serious medical or psychiatric illness likely to interfere with study participation,
including recent myocardial infarction (within the past 6 months) or poorly controlled
diabetes mellitus

- Hypersensitivity to bortezomib, boron, or mannitol

- Grade 2 or higher peripheral neuropathy



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Light Chain Deposition Disease
Primary Systemic Amyloidosis
Intervention(s)
Drug: bortezomib
Drug: dexamethasone
Drug: melphalan
Primary Outcome(s)
Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR]) After 3 Months (3 Cycles) of Therapy [Time Frame: Assessed at 3 months]
Secondary Outcome(s)
Secondary ID(s)
E4A08
NCI-2011-02010
U10CA021115
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 26/11/2014
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01078454
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history